The METEORIC-HF Study: The Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure with Reduced Ejection Fraction

Summary:
The METEORIC-HF study investigated whether Omecamtiv Mecarbil, a selective cardiac myosin activator, could improve exercise capacity in patients with HFrEF. Results showed no significant improvement in exercise capacity metrics, indicating that while Omecamtiv Mecarbil may offer other clinical benefits, it does not enhance exercise tolerance in this patient population.

Produced by: Dr. Ashish Correa, MD and Dr. Anu Lala, MD
Reviewed by: Dr. Teodora Donisan, Dr. Amit Goyal

CardioNerds Infographics

Explore our comprehensive collection of infographics, categorized by cardiovascular topics such as heart failure and transplantation, arrhythmias and electrophysiology, cardio-obstetrics, cardiovascular imaging, congenital heart disease, prevention, coronary artery disease, critical care, hypertension, pericardial disease, pulmonary hypertension, valvular heart disease, vascular disease, women’s cardiovascular health, diversity, inclusion, and more!

Feel free to download and share these visuals in presentations or on social media. Please use the infographics as provided—without altering or cropping out the creators’ credit.

For even more learning, explore the CardioNerds Tweetorial Page, featuring a curated collection of educational tweetorials!